Amylin Pharmaceuticals Inc announced that Ginger L. Graham has been named President and Chief Executive Officer, effective September 1, 2003. Graham recently worked with Guidant Corporation, a medical technology company, where she was Group Chairman, Office of the President. She was responsible for Guidant's global operations, producing revenues in excess of $3 billion.

Prior to her responsibilities as Group Chairman, she was President of the Vascular Intervention group of Guidant. In 1993, Graham was appointed President and CEO of Advanced Cardiovascular Systems, a subsidiary of Eli Lilly and Company and one of the predecessor companies of Guidant. She was part of the team that formed Guidant, taking it public in 1994. Graham started her career with Lilly where she held a variety of management roles in finance, sales, marketing and strategic planning. She completed an MBA at Harvard University in 1986.

"Now is the time to build Amylin's commercial enterprise capabilities and we believe bringing Ginger to lead our executive team is a critical part of Amylin's future," said Joseph C. Cook, Jr., current Chairman and Chief Executive Officer. "Ginger is recognized as a strong leader with particular expertise in building and managing commercial operations. During her seven-year tenure on Amylin's Board of Directors, she has chaired the Audit Committee and recently led a Board-level strategic review of our commercial plans for Symlin. With her past experiences and accomplishments, Ginger is the ideal person to lead Amylin into its next stage of growth."

Cook will remain in his current role until September 2003. After that time, he will continue as Chairman of the Board and will be actively involved in key strategic initiatives including Amylin's global collaboration agreement with Lilly for exenatide, investor relations, and plans for manufacturing capacity and supply. Cook has been a Director of Amylin since 1994, and the CEO since 1998.

"Amylin has two first-in-class compounds in late stage development for people living with diabetes, a disease widely viewed as a global epidemic," said Graham. "We are building an even broader biopharmaceutical company with significant programs targeted at metabolic disease, with the goal of fulfilling the promise of Amylin's research and development investments. I am very excited about our opportunities to develop valuable human medicines that may make a meaningful difference in the lives of millions of people. Joe's continuing role as Chairman, the leadership of Dan Bradbury and the rest of the management team, the confidence of our investors and the great team at Amylin provide a powerful foundation for the future. I am honored to join this team."

Amylin also announced that Daniel M. Bradbury has been named Chief Operating Officer, effective immediately. Bradbury has been with Amylin since 1994, most recently as Executive Vice President. He played an instrumental role in the successful negotiation of the broad-based agreement with Lilly for the global development and commercialization of exenatide, and through his leadership in corporate development and research, secured the addition of two programs to Amylin's development pipeline. Bradbury will have expanded responsibilities for the research, development and clinical capabilities of the Company.